Venus Remedies completes clinical trials for new FDC

Mumbai, Apr 10 (UNI) Venus Remedies Ltd has successfully completed the phase III clinical trials of the new formulation developed by its R&D wing with excellent results reported from all centres where the same were being carried out.

In a release to the BSE, the company said, it had begun its multi-centered phase III clinical trials for its new formulation, fixed dose combination drug of latest generation cephalosporin with an amino-glycoside, after receiving permission from the authorities for the same last year and now the permission is awaited for its commercial launch very shortly.

This product provides a sure shot remedy for both HAP (hospital acquired pneumonia) and CAP (community acquired pneumonia), and febrile neutropenia, a severe problem with critical care patients.

The results of clinical trials have proved that this new formulation is 25 times more effective than the alone fourth generation Cephalosporin, one of the components of this new FDC.

The company has already filed a Patent Application for its revolutionary formulation to Indian Patent Office and a PCT application is in process for international patent of the same.

The company shall be launching this new formulation under strategic marketing tie-up with leading pharma companies, with the brands and agreements already in place for launching the product in its niche segment, the release added.

UNI GC PP SKB1605